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Revisiting menstrual bleeding patterns in adolescents using
etonogestrel (ENG) implant
Anna Iddings, MD and Hatim A Omar,
MD
Division of Adolescent Medicine, Kentucky Children’s
Hospital, University of Kentucky College of Medicine,
Lexington, Kentucky, USA

Abstract
Etonogestrel (ENG) implant is an effective method of
contraception. The implant is designed to provide
contraceptive efficacy for three years with a relatively quick
return of fertility upon its removal. Dysfunctional uterine
bleeding (DUB) is a common side effect of long acting
progestins and is often the reason patients state for removal
or discontinuation. A retrospective chart analysis was
completed on 292 patients who chose to be on the ENG
implant. Age of patients ranged from 10-29 years of age
with the average age at implant being 17 years +/- 3 years.
Patients retained implant for 1-68 months with the average
use being 21.0 months +/- 15.5 months. Over the 69 month
period, 158 patients had the complaint of DUB (54.1%) and
46 patients with DUB had their implants removed because
DUB was unresolved upon treatment and/or follow up
(15.6%). Therefore, is it import for clinicians to be aware of
the likelihood of DUB with implant usage and for them to
be able to provide appropriate pre and post insertion
counseling and treatment to all of their patients.
Keywords: Dysfunctional uterine bleeding, etonogestrel,
adolescent contraception, abnormal uterine bleeding,
subdermal contraceptive implant
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There are more than 20 million women worldwide
who use long acting progesterone-only contraceptives
(1, 2). Implanon™ and its radiopaque version,
Nexplanon™, are Etonogestrel (ENG) implantable
rods that are placed subdermally. These implants offer
effective long term contraception for up to three years
with a failure rate of only 0.3-1.0% annually. The
implant is off-white, non-biodegradable rod of 4 cm
in length with a diameter of 2 mm. Each implant
contains 68 mg ENG and barium sulfate added to the
Nexplanon™ version to allow for it to be radiopaque
(3, 4). ENG prevents pregnancy by not just one but
three mechanisms; (i) suppresses luteinizing hormone
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surge and partially suppresses follicle stimulating
hormone (ii) increases viscosity of the cervical mucus
that to impede penetration by sperm (iii) thins the
endometrium to make implantation unlikely (3, 5, 6).
Studies show that ENG release from these
implants is slow, steady, and gradually decreases over
the 3 years of usage. One study showed that ENG
releases 60 to 70 ug in the first day of implant,
ensuring therapeutic levels are reached within the first
few days after implant. After the initial surge of ENG
release the rate decreases slightly to 40-45 μg/day
with a gradual decline to 25-30 μg/day at the end of
three years (5). This makes the 68 mg starting dosage
more than adequate to prevent pregnancy over the
three year duration of usage. Also of note is the quick
return to fertility following implant removal. Unlike
other long acting contraceptives, patients saw return
of fertility 1-2 weeks post ENG implant removal (5).
If used for the duration of the 3 years the ENG
implant is also very cost effective, and cheaper than
oral contraceptive pills as well as other hormonal
methods.
Despite the many appeals of the ENG implants
they are not without risks and unwanted side effects.
The number one reason cited for removal of the
implant is the troublesome side effect of dysfunctional
uterine bleed (DUB). A review of data from the
eleven clinical trials with Implanon™ found that
11.3% of users discontinued use due to bleeding
irregularities, mainly frequent or prolonged irregular
bleeding (3). Bleeding patterns vary from
amenorrhea, to spotting, to prolonged heavy bleeding
while on ENG implants (3, 4).
There are multiple causes of DUB. Causes
include altered endometrial matrix metalloproteinase
(MMP), irregular endometrial blood vessels,
increased vascular fragility, decreased glandular and
stromal support, and decreased epithelium integrity
(5-7). A variety of treatments target these different
mechanisms, with some treatments being more
effective than others. Most common treatments
include: Doxycycline, Mifepristone, Combination
Oral Contraceptive, or NSAIDs. However, it should
be noted that although these treatments may resolve a
current episode of DUB, there has been no data to
show long term improvement in subsequent bleeding
patterns (1).

In Implanon™ users, the bleeding pattern is most
likely to vary within the first three months post
implant (5, 6). This can lead to frustration especially
in an adolescent population which is so often more
focused on the here and now than 3 months in the
future. Since treatment is not always effective, it is
important to discuss removal on a case by case basis.
In supporting women’s contraception needs it is
important to remember and accept that all women
have different levels of toleration for DUB and other
side effects. Some women simply cannot tolerate the
implant and encouraging retention without dealing
with the distressing side effects may be
counterproductive (8). This article focus is on DUB in
adolescent ENG implant users, the treatment and
counseling provided for DUB, and how treatment or
lack of treatment contributed to the desire for implant
removal in our patient population.

Methods
We conducted a chart review of the patients who
received the ENG implant in our adolescent clinic. An
analysis was completed based on symptoms
experienced by patients who were on ENG implant
and their management, which in some cases resulted
in its removal. Patients who received implants on or
after February of 2008 were included in this study
(n=292). DUB was classified by amount of time and
heaviness of flow and assigned a number 1-5 (see
table 1). Any patient who was not amenorrheic was
ultimately classified as a patient with DUB.
Table 1. Classifying Dysfunctional Uterine Bleed

1
2
3
4
5

Amenorrhea
Spotting for <7 days/month
Spotting for >7 days/ month
Heavy bleeding for <7 days per month
Heavy bleeding for >7 days per month

Results
From February 2008 to November 2013 a total of 292
patients had either Implanon™ or Nexplanon™
placed by a certified and trained clinician in the
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Division of Adolescent Medicine, University of
Kentucky, Lexington, KY, USA. The patient
demographics of this clinic are summarized in table 2.
We also looked at other high risk behaviors such
as whether or not patients were sexually active at time
of implant placement (see table 3). This data is

relevant as prevention of unwanted pregnancy is
especially important in patients with co morbid
conditions such as substance abuse and sexually
transmitted infections that could cause harm to an
early developing fetus.

Table 2. Demographics of implant users at University of Kentucky Adolescent Clinic
Age at Placement
Mean
17 years old
SD
3 years
Range
10-29 y/o

Race
White
Black
Hispanic
Other

52.7%
45.2%
1.4%
0.7%

Insurance
Private
Medicaid

70.9%
29.1%

Occupation
Student
Employed
Unemployed

83.9%
11.0%
4.8%

Table 3. High risk behaviors associated with implant users at University of Kentucky Adolescent Clinic
at time of placement
Sexually Active
Yes
67.8%
No
30.1%
Unknown
2.1%

Smoking Status
Current
22.6%
Prior
9.6%
Never
64.7%
Unknown
3.1%

Substance Abuse
Current
22.6%
Prior
9.6%
Never
22.6%
Unknown
4.5%

The age range of patients receiving implant was
between 10 and 29 years. The number of months the
patient retained their implant post insertion ranged
from 0 month (26 days) to 69 months, average 21.0
months +/-15.5 months before they were electively
removed.
DUB was classified on a scale from 1-5 (see table
1) and was managed in a variety of ways depending

Age of First Intercourse
Average
14.5
SD
2.1
Range
10-21 years

Prior STDs
Yes
28.1%
No
66.8%
Unknown
5.1%

on patient and classification of DUB. Treatment was
left up to the clinician’s discretion. As seen in table 4,
the most common treatment was combined oral
contraceptive pills alone (31.5% of patients with
DUB). Resolution of DUB was also variable, which
helps to emphasize the importance of careful follow
up and continued counseling post treatment of DUB.

Table 4. Treatment of patients with DUB

OCPs and Follow Up
Naproxen Only
OCPs and Naproxen
Reassurance and Follow Up
No Treatment or Refused Treatment

% Treated
31.5%
1.4%
2.4%
13.0%
6.5%

In our experience 54.1% of patients experienced some
level of DUB (158 out of 292). Also noteworthy is
that 65.2% of patients inciting DUB were treated with
some sort of pharmacological method (OCPS,
Naproxen, or Both), while 13.0% seen in clinic
received only reassurance and follow up. Over the 69
months of this study, 86 of 292 patients had their
implants removed. Although DUB was the

% Resolution with Treatment
66.3%
75.0%
85.7%
86.8%
56.2%

overwhelming reason for removal in our patient
population, table 5 depicts other reasons why the
device was removed. Of interest is that 5.8% of all
patients, and 17.9% of all patients presenting for
implant removal, chose to get a new ENG implant
placed upon expiration of their old implant,
suggesting these patients were pleased with this form
of contraception.
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Table 5. Reasons for implant removal

Dysfunctional Uterine Bleed
Implant Expired, New Implant Placed
Implant Expired, Patient Switched to Another Form of Birth Control
Other* Reason Stated for Removal
Implant Has Not Been Removed

15.8%
5.8%
2.7%
5.1%
70.5%

* “Other” reasons for removal included; cramping, weight gain, pain at implant site, mood disturbances, and patient desiring
pregnancy.

In the end 46 of 158 patients citing DUB opted
for removal of the implant (29.1% DUB patients and
15.8% of all patients receiving ENG implant). Of
these 46 patients, the average time of implant usage
was 16 months +/- 11 months. In comparison to a
prior smaller scale study done at our institution
looking at ENG implant and DUB, 15 of 58 patients
(22.4%) opted for removal because of DUB, with a
mean usage of 10.9 months. This would suggest that
our clinicians are doing a better job of counseling and
treating patients with DUB due to ENG implant use,
and stresses the importance of clinicians being
informed and competent at informing patients about
side effects of ENG implant usage.

Discussion
Long acting progesterone contraceptive are extremely
effective in preventing teen pregnancies, which is
why it is often a contraceptive method of choice for
patients in our Adolescent Medicine Clinic, especially
those patients participating in high risk behaviors.
However, DUB is one of the major reasons for the
discontinuation and removal of the implant. There are
patient specific recommendations to manage DUB
which include: doxycycline, EE, mifepristone,
combination oral contraceptives, and NSAIDs. Of
these treatments none are guaranteed to resolve DUB
or prevent future DUB. Therefore, it is crucial for
clinicians to provide the patient with adequate pre and
post insertion counseling, as well as adequate preremoval counseling so that patients can have
reasonable expectations of what side effects could
occur with implant usage. Also due to the quick return
to fertility upon implant removal, it is equally
important to provide post removal recommendations
for alternative contraceptive methods to prevent

unintended pregnancy, especially in high risk
adolescent populations. This study shows high
prevalence of discontinuation of the method, because
of bleeding. However, in adolescent population at
high risk of unwanted pregnancy, it is still an
effective, long acting method that should continue to
be utilized with proper counseling and follow up.
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